Compared to platinum-based chemotherapy, the treatment with PARP inhibitors plus platinum showed a substantially higher OR for thrombocytopenia (OR 1.10, 95% CI 1.00, 1.21) but no significant differences were noted for most adverse events. The gene discussed is PARP1; the disease is Thrombocytopenia.